Latest Pharmaceutical News and Updates : Pharmaceutical updates, Pharmaceutical News , Pharmaceutical around the world

Nishadil

Washington | 14°C (clear sky)

Nektar Therapeutics Charts a Course Forward: Q2 2026 Sees Strategic Investment Amidst Financial Shifts

Top story

Nektar Therapeutics Charts a Course Forward: Q2 2026 Sees Strategic Investment Amidst Financial Shifts

In focus

Latest feed

The High-Stakes Battle: Why Pharmacy Benefit Managers Are Fighting Tooth and Nail

Cipla Shares Poised for a Jump as Citi Flags Near‑Term US Growth Triggers

The Eli Lilly Rollercoaster: Deciphering a Volatile Week in the Market

A Strategic Pause: Gilead Adjusts Timeline for Arcellx Acquisition

Latest headlines

Engene Holdings: Why 2026 Could Be Their Pivotal Moment

Engene Holdings: Why 2026 Could Be Their Pivotal Moment

An Unexpected Turn: America's Drug Price Paradox

An Unexpected Turn: America's Drug Price Paradox

The FDA's Risky Gamble: Incentivizing Speed in Drug Approvals

The FDA's Risky Gamble: Incentivizing Speed in Drug Approvals

GSK's Bold Gambit: $1.4 Billion Bet on Aiolos Bio for Pulmonary Hypertension Breakthrough

GSK's Bold Gambit: $1.4 Billion Bet on Aiolos Bio for Pulmonary Hypertension Breakthrough

Moderna's Big Turnaround: Why Jim Cramer is Eyeing 2026 for Revenue Growth

Moderna's Big Turnaround: Why Jim Cramer is Eyeing 2026 for Revenue Growth

Behind the Headlines: A Deep Dive into This Week's Biggest Corporate Moves

Behind the Headlines: A Deep Dive into This Week's Biggest Corporate Moves

Big Pharma Breaks Silence: Confronting RFK Jr. on Vaccines

Big Pharma Breaks Silence: Confronting RFK Jr. on Vaccines

More Than Business: Incyte's Identity Forged in the Blood Cancer Battle

More Than Business: Incyte's Identity Forged in the Blood Cancer Battle

Delhi Pollution's Unseen Cost: Akums Drugs CFO Exits Amid IPO Preparations

Delhi Pollution's Unseen Cost: Akums Drugs CFO Exits Amid IPO Preparations

Biohaven's Balancing Act: Cash Cushion Grows, But So Does the Dilution Shadow

Biohaven's Balancing Act: Cash Cushion Grows, But So Does the Dilution Shadow

A Game-Changer for Assembly Bio: Gilead's Nod Sends Stock Soaring

A Game-Changer for Assembly Bio: Gilead's Nod Sends Stock Soaring

A New Chapter for Wockhardt? Chairman 'Very Confident' on Novel Antibiotic's USFDA Acceptance

A New Chapter for Wockhardt? Chairman 'Very Confident' on Novel Antibiotic's USFDA Acceptance

Eli Lilly's Trillion-Dollar Triumph: Reshaping the Pharma Landscape

Eli Lilly's Trillion-Dollar Triumph: Reshaping the Pharma Landscape

The Jemperli Royalty Rumble: GSK's Tesaro Unit Takes AnaptysBio to Court

The Jemperli Royalty Rumble: GSK's Tesaro Unit Takes AnaptysBio to Court

The Biotech Boom: Why a Frenzy of Mergers Signals Big Wins Ahead

The Biotech Boom: Why a Frenzy of Mergers Signals Big Wins Ahead

The Biotech Rollercoaster: Moderna Defies Gravity with a Q3 Power Play

The Biotech Rollercoaster: Moderna Defies Gravity with a Q3 Power Play

The Earnings Game: Big Tech's Bumpy Ride and the Surprises That Moved Markets

The Earnings Game: Big Tech's Bumpy Ride and the Surprises That Moved Markets

From Reliance to Resilience: India's Bold Push for a Nipah Cure

From Reliance to Resilience: India's Bold Push for a Nipah Cure

The Unstoppable Ascent: How Linzess Propelled Ironwood to Staggering Heights

The Unstoppable Ascent: How Linzess Propelled Ironwood to Staggering Heights

Regeneron's Remarkable Q3: A Dupixent-Driven Triumph That Reaffirms Biotech's Pulse

Regeneron's Remarkable Q3: A Dupixent-Driven Triumph That Reaffirms Biotech's Pulse

Hyderabad's Biotech Beat: Why the Government's Still All In on Life Sciences

Hyderabad's Biotech Beat: Why the Government's Still All In on Life Sciences

The Biotech Dance: Novartis Eyes Avidity in a Blockbuster Bid

The Biotech Dance: Novartis Eyes Avidity in a Blockbuster Bid

CorMedix's DefenCath Ignites Stellar Q3 Performance, Elevating Full-Year Revenue Projections

CorMedix's DefenCath Ignites Stellar Q3 Performance, Elevating Full-Year Revenue Projections

Lyra Therapeutics Gambles on Higher Dose in New Phase 3 Trial Following Previous Setback for Chronic Rhinosinusitis Treatment

Lyra Therapeutics Gambles on Higher Dose in New Phase 3 Trial Following Previous Setback for Chronic Rhinosinusitis Treatment

A New Horizon in Breast Cancer Treatment: AstraZeneca's Datroway Extends Lives and Boosts Hopes

A New Horizon in Breast Cancer Treatment: AstraZeneca's Datroway Extends Lives and Boosts Hopes

Massachusetts' Biopharma Giant, Takeda, Announces Significant Layoffs Impacting 137 Employees in Cambridge Amidst Industry Restructuring

Massachusetts' Biopharma Giant, Takeda, Announces Significant Layoffs Impacting 137 Employees in Cambridge Amidst Industry Restructuring

Telangana's Trillion-Dollar Leap: Eli Lilly Injects $1 Billion, Reshaping India's Pharma Future

Telangana's Trillion-Dollar Leap: Eli Lilly Injects $1 Billion, Reshaping India's Pharma Future

Maharashtra Assures Safety: No Coldrif Syrup Found in State

Maharashtra Assures Safety: No Coldrif Syrup Found in State

India's Urgent Crusade: A Nationwide Crackdown on Contaminated Drugs After Tragic Child Deaths

India's Urgent Crusade: A Nationwide Crackdown on Contaminated Drugs After Tragic Child Deaths

Crucial Medicare Drug Price Loophole Fix Stalled: A Setback for Patient Savings

Crucial Medicare Drug Price Loophole Fix Stalled: A Setback for Patient Savings

Empowering Patients: Bristol-Myers Squibb Unveils Enhanced Digital Support for Opdivo

Empowering Patients: Bristol-Myers Squibb Unveils Enhanced Digital Support for Opdivo

Pfizer's Pivotal Leap: BMO Analyst Seigerman Declares Bullish Outlook on Long-Awaited Obesity Market Entry via Metsara Deal

Pfizer's Pivotal Leap: BMO Analyst Seigerman Declares Bullish Outlook on Long-Awaited Obesity Market Entry via Metsara Deal

MBX Biosciences Rockets Skyward: Breakthrough Hypoparathyroidism Drug Unlocks Massive Pre-Market Surge!

MBX Biosciences Rockets Skyward: Breakthrough Hypoparathyroidism Drug Unlocks Massive Pre-Market Surge!

The Epigenetics Revolution: Unlocking a $70 Billion Future by 2034

The Epigenetics Revolution: Unlocking a $70 Billion Future by 2034

Ocugen Stock Rockets Upward: Unpacking the Latest Biotech Buzz

Ocugen Stock Rockets Upward: Unpacking the Latest Biotech Buzz

Aurobindo Pharma Under the Microscope: 8 USFDA Observations Rock Shares

Aurobindo Pharma Under the Microscope: 8 USFDA Observations Rock Shares

Cell Therapy Manufacturing Market Set to Skyrocket to $18.89 Billion by 2034, Fueled by Chronic Disease Epidemic and Biotech Advancements

Cell Therapy Manufacturing Market Set to Skyrocket to $18.89 Billion by 2034, Fueled by Chronic Disease Epidemic and Biotech Advancements

Sanofi's Eczema Breakthrough: A Scientific Triumph Meets a Skeptical Wall Street

Sanofi's Eczema Breakthrough: A Scientific Triumph Meets a Skeptical Wall Street

Load more